ZOFENOPRIL CALCIUM

Synonyms. Zofenopril calcium; Bifril; Zofenil; Zoprace; (4S)-1-((2S)-3-(benzoylthio)-2-methyl-1-oxopropyl)-4-(phenylthio)-L-proline calcium salt; (4S)-N-((S)-3-Mercapto-2-methylpropionyl)-4-(phenylthio)-L-proline benzoate calcium salt;

ZOFENOPRIL

Click for original image

 

PRODUCT IDENTIFICATION

CAS RN

81938-43-4

EINECS RN

 

FORMULA

 C22H22NO4S2·1/2Ca

MOLE WEIGHT

448.58

H.S CODE

 2933.99.5300

SMILES

 [Ca+2].C([C@H]1N(C([C@@H](CSC(=O)c2ccccc2)C)=O)C[C@H](C1)Sc1ccccc1) (=O)[O-].C([C@H]1N(C[C@H](C1)Sc1ccccc1)C([C@@H](CSC(c1ccccc1)=O)C)= O)(=O)[O-]

CLASSIFICATION

ACE inhibitor. Antihypertensive

EXTRA NOTES

Zofenopril is a long-lasting, lipophilic ACE inhibitor. Zofenopril is also an inhibitor of PEPT2, the predominant peptide transporter in kidney and choroid plexus.

 

PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE.

white crystalline powder

MELTING POINT

>250 C

BOILING POINT

 

DENSITY

 

SOLUBILITY IN WATER

 

SOLVENT SOLUBILITY

 

VAPOR DENSITY

 

log P(octanol-water)

 3.5

VAPOR PRESSURE

  

AUTOIGNITION TEMP

  
pH

 

REFRACTIVE INDEX

 

FLASH POINT

 

 

STABILITY AND REACTIVITY
STABILITY Stable under normal conditions.

INCOMPATIBLE MATERIALS

Strong acids and oxidizing agents

POLYMERIZATION

Has not been reported

NFPA RATINGS

Health: 1, Flammability:0, Reactivity: 0

 

EXTERNAL LINKS & GENERAL DESCRIPTION

Wikipedia Linking - Zofenopril

Google Scholar Search - Zofenopril

Drug Information Portal (U.S. National Library of Medicine) - Zofenopril

PubChem Compound Summary - Zofenopril

KEGG (Kyoto Encyclopedia of Genes and Genomes) - Zofenopril

Chemical Entities of Biological Interest (ChEBI) - Zofenopril

http://www.ncbi.nlm.nih.gov/ - Zofenopril

Human Metabolome Database - Zofenopril

http://www.tandfonline.com/
Zofenopril, a new potent sulphydryl angiotensin-converting enzyme (ACE) inhibitor, is characterized by high lipophilicity, selective cardiac ACE inhibition, and antioxidant and tissue protective activities. In vitro and in vivo experiments suggest that zofenopril exerts antioxidant properties at clinically achievable tissue concentrations. In endothelial cells, zofenopril enhances nitric oxide production, attenuates atherosclerotic lesion development and inhibits adhesion molecule expression by reducing reactive oxygen species. These peculiar characteristics are reflected in the drug's cardioprotective activity, which has been shown to be greater than that of non-sulphydryl ACE inhibitors. Cardiac hypertrophy was also reduced by chronic zofenopril administration, independently of its blood pressure-reducing effect. ACE inhibitors with a sulphydryl group could have an advantage in improving vascular function and reducing cardiac impairment compared with nonsulphydryl- containing ACE inhibitors. This could explain zofenopril’s remarkable clinical efficacy post-infarction, and potentially beneficial use in prevention and therapy of cardiovascular diseases, such as atherosclerosis, thrombosis and heart failure.

 

SALES SPECIFICATION

APPEARANCE

white crystalline powder

PURUTY

98.0% min

LOSS ON DRYING

5.0% max

HEAVY METALS

20ppm max

OPTICAL ROTATION

-65° ~ -70° (c = 1 in methanol/HCl)

MELTING POINT

>250 C

 

TRANSPORT & REGULATORY INFORMATION

UN NO.

3077

HAZARD CLASS

 9
PACKING GROUP III

 

SAFETY INFORMATION

HAZARD OVERVIEW

OSHA Hazards: No known OSHA hazards. GHS Classification: Acute aquatic toxicity (Category 1), Chronic aquatic toxicity (Category 1). Very toxic to aquatic life with long lasting effects. Inhalation: May be harmful if inhaled. May cause respiratory tract irritation. Eyes: May cause eye irritation. Skin: May be harmful if absorbed through skin. May cause skin irritation. Ingestion: May be harmful if swallowed.

GHS

  

SIGNAL WORD

Warning

PICTOGRAMS

HAZARD STATEMENTS

H410

P STATEMENTS

P273-P501

EC DIRECTIVES

 

HAZARD CODES

RISK PHRASES

50/53

SAFETY PHRASES

 60-61

 

PACKING

Preserve in light-resistant and well-closed containers

 

PRICE INFORMATION